KnE Medicine
ISSN: 2519-125X
The latest conference proceedings on all fields of medicine.
Cut-off Value of Testosterone and FSH Level In Patient With Azoospermia
Published date: Oct 04 2016
Journal Title: KnE Medicine
Issue title: The 6th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2016)
Pages: 145-152
Authors:
Abstract:
Follicle-stimulating hormone(FSH) and Testosterone are important for spermatogenesis. Increased serum FSH and decreased testosterone are related to abnormal spermatogenesis. Azoospermia can be classified as obstructive and non-obstructive azoospermia. This study aims to discover cut-off value of Testosterone and FSH in predicting obstructive and non-obstructive azoospermia. From 1064 patients, 120 fulfilled inclusion and exclusion criteria. There were 66.7% in obstructive with 33.3% in non-obstructive group. No difference in terms of age (36,83 vs 36,62 y.o). Testosterone were 405.54 + 186.14 ng/dL vs 298.84 + 161.45 ng/dL (p=0.002) while FSH was 8,53 + 8,43 mIU/mL vs 20,12 + 11,89 mIU/mL (p<0.001) for obstructive and non-obstructive azoospermia respectively. Average testicular were 17.74 + 4.03 cc and 17.50 + 4.23 cc while in non-obstructive group are 12.97 + 5.18 cc and 13.37 + 5.31 cc for right and left testis respectively. FSH value above 10.36 mIU/mL has sensitivity 82.1% and specificity 79.5% for predicting non-obstructive azoospermia. Unfortunately, Testosterone could not be used in predicting azoospermia classification. Obstructive and non-obstructive azoospermia could be predicted using FSH but not testosterone serum level. Higher testosterone population should be used for further study.
References:
[1] A. Mendeley, Definitions Of Infertility And Recurrent Pregnancy Loss: A Committee Opinion, Fertil Steril, 99, no. 1, p. 63, (2013).
[2] S. Rutstein and I. Shah, Infecundity, Infertility, And Childlessness In Developing Countries, Dhs Comparative Reports 9, Dhs Comp Reports, 9, 13–50, (2004).
[3] T. Bushnik, J. L. Cook, A. A. Yuzpe, S. Tough, and J. Collins, Estimating the prevalence of infertility in Canada, Human Reproduction, 27, no. 3, 738–746, (2012).
[4] Y. Che and J. Cleland, Infertility in Shanghai: Prevalence, treatment seeking and impact, Journal of Obstetrics and Gynaecology, 22, no. 6, 643–648, (2002).
[5] G. Bayasgalan, D. Naranbat, J. Radnaabazar, T. Lhagvasuren, and P. J. Rowe, Male infertility: Risk factors in Mongolian men, Asian Journal of Andrology, 6, no. 4, 305– 311, (2004).
[6] J. Farhi and A. Ben-Haroush, Distribution of causes of infertility in patients attending primary fertility clinics in Israel, Israel Medical Association Journal, 13, no. 1, 51–54, (2011).
[7] C. Krausz, Male infertility: Pathogenesis and clinical diagnosis, Best Pract Res Clin Endocrinol Metab [Internet], 25, no. 2, 271–285, (2011)., Available from http://dx. doi.org/10.1016/J.Beem.2010.08.006.
[8] A. D. Geidam, K. D. T. Yawe, A. E. A. Adebayo, and A. Idrisa, Hormonal profile of men investigated for infertility at the University of Maiduguri in northern Nigeria, Singapore Medical Journal, 49, no. 7, 538–541, (2008).
[9] A. Jungwirth, A. Giwercman, H. Tournaye, T. Diemer, Z. Kopa, G. Dohle, and C. Krausz, European association of urology guidelines on male infertility: The 2012 update, European Urology, 62, no. 2, 324–332, (2012).
[10] W. J. Bremner, A. M. Matsumoto, A. M. Sussman, and C. Paulsen, Follicle-stimulating hormone and human spermatogenesis, Journal of Clinical Investigation, 68, no. 4, 1044–1052, (1981).
[11] S. R. Babu, M. D. Sadhnani, M. Swarna, P. Padmavathi, and P. P. Reddy, Evaluation of FSH, LH and testosterone levels in different subgroups of infertile males, Indian Journal of Clinical Biochemistry, 19, no. 1, 45–49, (2004).
[12] G. Adamson and V. Baker, Subfertility: Causes, Treatment and Outcome, Best Pract Res Clin Obstet Gynaecol, 17, no. 2, 169–85, (2003).
[13] M. S. Wosnitzer and M. Goldstein, Obstructive azoospermia, Urologic Clinics of North America, 41, no. 1, 83–95, (2014).
[14] Dh. Seno, P. Birowo, N. Rasyid, and A. Taher, Etiologies Of Male Infertility in Dr . Cipto Mangunkusumo Hospital, Jakarta. Indones, J Obstet Gynecol, 35, no. 3, 130–4, (2011).
[15] R. Kumar, Medical Management Of Non-Obstructive Azoospermia, Clinics [Internet], 68, no. S1, 75–9, (2013).
[16] S.-C. Chen, J.-T. Hsieh, H.-J. Yu, and H.-C. Chang, Appropriate cut-off value for folliclestimulating hormone in azoospermia to predict spermatogenesis, Reproductive Biology and Endocrinology, 8, article no. 108, (2010).
[17] E. M. Sussman, A. Chudnovsky, and C. S. Niederberger, Hormonal Evaluation of the Infertile Male: Has It Evolved? Urologic Clinics of North America, 35, no. 2, 147–155, (2008).
[18] L. C. Garcia Diez, J. M. Gonzalez Buitrago, J. J. Corrales, E. Battaner, and J. M. Miralles, Hormone levels in serum and seminal plasma of men with different types of azoospermia, Journal of Reproduction and Fertility, 67, no. 1, 209–214, (1983).
[19] D. G. Goulis, P. Polychronou, T. Mikos, G. Grimbizis, S. Gerou, V. Pavlidou, A. Papanikolaou, B. C. Tarlatzis, I. N. Bontis, and I. Papadimas, Serum inhibin-B and follicle stimulating hormone as predictors of the presence of sperm in testicular fine needle aspirate in men with azoospermia, Hormones, 7, no. 2, 140–147, (2008).
[20] V. Gowri, Kp. Venkiteswaran, I. Al-Zakwani, J. Mathew, Ka. Rahman, and M. AlMarhoon, Comparison Of The Demographics, Semen Parameters And Hormone Profiles In Men With Primary And Secondary Infertility. Sultan Qaboos Univ Med, 10, no. 3, p. 350, (2010).
[21] T. Modarresi, H. Hosseinifar, A. D. Hampa, M. Chehrazi, J. Hosseini, F. Farrahi, F. Dadkhah, M. Sabbaghian, and M. A. S. Gilani, Predictive factors of successful microdissection testicular sperm extraction in patients with presumed sertoli cellonly syndrome, International Journal of Fertility and Sterility, 9, no. 1, 107–112, (2015).
[22] C. F. Bryson, R. Ramasamy, M. Sheehan, G. D. Palermo, Z. Rosenwaks, and P. N. Schlegel, Severe testicular atrophy does not affect the success of microdissection testicular sperm extraction, Journal of Urology, 191, no. 1, 175–178, (2014)